Decoding Cancer Plasticity for
Human-Relevant Drug Response.
Delivering early insights into treatment efficacy and resistance using next-generation functional assays with exceptional biological fidelity.
Scroll
Decoding Cancer Plasticity for
>90%
of drug candidates fail in human trials.
Because preclinical models don’t predict human reality. Cymoplive bridges that gap with human-relevant tumor biology.
€50–60B
lost every year in failed oncology R&D
Late-stage failure is the most expensive mistake in drug development. Cymoplive reduces risk before it becomes loss.
50–100M
animals used annually in research
Yet translation to human cancer remains unreliable. Cymoplive delivers predictive human tumor insight without dependence on animal models.
Cancer Drug Failure Isn't About Wrong Targets.
It's About Undetected Adaptation.
Oncology failure is not driven only by incorrect targets. It is driven by the ability of cancer to evolve under therapeutic pressure.
Most screening systems measure early response, but they do not assess how tumors adapt and develop resistance. These escape mechanisms often remain undetected until after extensive and costly animal studies, or even during clinical trials, while important development decisions are based on short-term data.
This gap increases risk, cost, and lost opportunity.
Cymoplive Reveals What Is Difficult to Detect in Conventional Models
Cancer cells often do not simply die in response to therapy. Instead, they survive through adaptive, non-genetic changes that are difficult to detect in conventional models.
Cymoplive makes these dynamic cellular adaptations visible for the first time ever, enabling the identification of resistance mechanisms that typically remain undetected in early screening systems.
Our Technology
Breakthrough Discoveries
01
MarGel™
Our proprietary organ-like hydrogel engineered to recreate human-relevant physiological conditions and preserve tumour heterogeneity as observed in human cancers.
02
OncoTrix™
OncoTrix™ is a first-in-class platform that uses structured conditions to reveal functional adaptive behaviours of cancer cells missed by existing systems.
03
CellTraceD™
Live behavioural scoring that converts adaptive behaviour into actionable measures of cancer aggressiveness, drug efficacy pharmacodynamics, resistance/relapse risk, and combination performance.
Advancing Predictive Oncology Models
Cymoplive is a proprietary platform that delivers time-resolved insights into tumor adaptive behaviour under controlled experimental conditions.
Our platform and analytical framework have been validated in human carcinoma models, including pancreatic, triple-negative breast, and cervical cancers, demonstrating robust and reproducible performance across indications.
Cancer
Breast
Cancer
Advanced Features Engineered for Precision.
BR
LU
HE
LI
KI
ST
01
Organ-Mimicking Conditions
Customizable organ-specific tumor microenvironments that deliver clinically relevant insights.
02
High-Throughput Capability
Run multiple experiments simultaneously, accelerating discovery with optimised resource utilisation.
Migration
Toxicity
Viability
Adaptation
03
One Assay, Multiple Studies.
Extract migration, toxicity, viability, and adaptation data from a single, precious sample — without splitting or repeating assays.
04
High-Content Screening
Capture comprehensive, multiparametric data from every experiment instead of relying on a single endpoint.
05
Pharmacodynamic Readouts
Precision pharmacodynamic insights that guide mechanism validation, dose optimisation, and clinical strategy.
Funding & Core Partners
Act Before Resistance Becomes Expensive
Gain early insight into resistance risk and make smarter pipeline decisions, in collaboration with Cymoplive.